LELYSTAD, The Netherlands, September 14, 2010 /PRNewswire/ -- Pepscan Therapeutics (Pepscan), the Netherlands based biotechnology firm focusing on protein mimicry technology for the generation of novel therapeutics, today announced that it has signed a Research and License Agreement with Tibotec Pharmaceuticals, Ireland (Tibotec). Under the agreement Pepscan using its CLIPS technology will work with Tibotec to develop novel therapeutic peptides against an undisclosed target. Under the terms of the agreement, Pepscan will receive R&D funding and could receive payments on the achievement of research and clinical milestones, as well as royalties on sales of products resulting from the collaboration. Financial details of the agreement were not disclosed.
"Pepscan has recently realigned its R&D program to focus on the application of its proprietary CLIPS protein mimicry technology for the generation of novel therapeutic peptides and immunogens," said Wim Mol, CEO of Pepscan. "We are very pleased that Tibotec has decided to enter into a collaboration agreement with Pepscan that will utilize the CLIPS technology. We are convinced that our strong technology and expertise can yield improved peptides with superior activity and proteolytic stability, all this with a significantly shorter peptide." "We consider this agreement a further expression of our leadership position in the field of protein mimicry," he added.
About Pepscan Therapeutics
Pepscan Therapeutics is a privately held company based in Lelystad, The Netherlands. Pepscan is using its proprietary high throughput CLIPS protein mimicking technology for the development of novel constrained therapeutic peptides and immunogens. Besides its pipeline of proprietary anti- GPCR monoclonal antibody products Pepscan has various ongoing collaborations with leading pharmaceutical and biotech companies to develop novel therapeutics based on the proprietary CLIPS technology.
About CLIPS technology
CLIPS (Chemical LInkage of Peptides onto Scaffolds) is a technology to present one or more peptides in a structurally constrained configuration. These molecules behave as functional mimics of complex protein domains. CLIPS peptides have been used in antibody and vaccine programs to create superior immunogens in the generation of antibodies against disease relevant protein targets. This is especially valuable in the case of proteins that are inaccessible as recombinant proteins, such as GPCRs.
http://www.pepscantherapeutics.com
SOURCE Pepscan Therapeutics